Beckman Coulter’s SARS-CoV-2 IgG antibody test receives FDA EUA

Beckman Coulter’s  Access SARS-CoV-2 IgG assay has received Emergency Use Authorization (EUA) from the FDA. Beckman Coulter has already shipped tests to more than 400 hospitals, clinics and diagnostics laboratories in the U.S., and has begun distribution of the new antibody test globally to countries that accept the FDA EUA and CE Mark.

“At a time when significant confusion was created by the initial influx of poor-quality antibody tests, our team worked meticulously to develop a highly sensitive and specific assay,” said Julie Sawyer Montgomery, president of Beckman Coulter. “With 100% Positive Percent Agreement and 99.6% Negative Percent Agreement, our test significantly reduces the risk for false positives, delivering the results that health care providers and their patients can trust. A lot has been written about accuracy issues with the initially launched antibody tests, but a test at this level offers positive predictive values greater than 90% even in very low prevalence communities. And, in areas hardest hit by the virus, the positive predictive values of our assay are greater than 98%.”1,2

Additionally, of the tests developed by the top four in vitro diagnostic manufacturers capable of delivering high-volume testing to the U.S., Beckman Coulter’s test is the only SARS-CoV-2 IgG assay which targets antibodies that recognize the receptor binding domain (RBD) of the spike protein which SARS-CoV-2 uses to bind to a human cell receptor. This is significant as antibodies which target the RBD have the potential to be neutralizing and thus prevent future infection by blocking the virus from entering the cell. It is for this reason many vaccine developers are also targeting the RBD of the spike protein in their vaccine development.3

Beckman Coulter has more than 16,000 immunoassay analyzers worldwide, 3,500 of which are in the United States. Many of Beckman Coulter’s analyzers can deliver up to 400 routine tests an hour, says the company. A large number of analyzers are connected to hospital information systems, enabling laboratories to automate the reporting of serology test results. The Access SARS-CoV-2 IgG test can also be run on Beckman Coulter’s Access 2 analyzer, a compact table-top analyzer enabling high-quality serology testing to be carried out in small hospitals and clinics. This test seamlessly integrates into laboratory workflows making it easier to add serology testing to routine blood tests performed during inpatient and wellness testing. This type of testing can enable health systems to comprehensively determine the immune status of their communities and potentially identify individuals that are eligible for future plasma donation.

Understanding Immunity
“We anticipate that understanding the immune status of communities and convalescent plasma donation will play important roles in the fight against COVID-19 before a vaccine is widely available,” commented Shamiram R. Feinglass, M.D., MPH, chief medical officer Beckman Coulter. “While there is more to learn regarding how long an individual’s immune response to the SARS-CoV-2 virus lasts, this test may be crucial to determining the portion of the population that may already be immune.”

“Our assay can be utilized in a variety of healthcare settings, including central laboratories, as well as smaller clinics and hospitals in underserved communities with a range of Beckman Coulter immunoassay analyzers,” added Sawyer Montgomery. “This accessibility is vital to ensuring all communities, including minority, rural and urban have access to this testing and answers they can trust.”

While immunoglobulin M (IgM) antibodies play a prominent role in the body’s primary antibody response to infection, they decline within a short timeframe. IgG antibodies begin developing within the first 14 days, and may last for months or years depending upon the pathogen and the individual.

“We developed the Access SARS-CoV-2 IgG test to help clinicians determine if a patient was infected with COVID-19 in the past and developed an immune response,” stated Feinglass. “In contrast, a total antibody test can’t help a clinician determine whether an individual is currently infected or whether they developed an immune response from an earlier infection. The clinician must therefore perform additional testing, requiring added time and cost.”

References:
1 At 3.5% prevalence rate, PPV is 90.1%; at 16% prevalence rate PPV is 97.9%. When equivocal results are excluded, a 2% prevalence rate yields a 91.1% PPV and a 16% prevalence rate yields 99% PPV.
2 Koenig, D. Evidence Mounts for Greater COVID Prevalence, WebMD, https://www.webmd.com/lung/news/20200424/more-data-bolsters-higher-covid-prevalence
3 Grifoni, A., et al., Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals, Cell (2020), prepublication, doi: https://doi.org/10.1016/j.cell.2020.05.015

MB Bureau

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.